论文部分内容阅读
目的探讨重组人白细胞介素-Ⅱ(rhIL-Ⅱ)联合长春新碱治疗激素无效特发性血小板减少性紫癜(ITP)患者的临床疗效及安全性。方法选取2008年12月～2011年12月在我院血液内科住院治疗的112例激素无效ITP患者为研究对象,应用随机数字表法将患者分为对照组和观察组。对照组患者给予长春新碱,而观察组患者则加用rhIL-Ⅱ进行治疗,比较对照组和观察组患者临床疗效及药物不良反应发生情况。结果观察组患者治疗总有效率(85.71%)明显高于对照组的(69.64%),比较差异有统计学意义(P<0.05)。两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论rhIL-Ⅱ联合长春新碱治疗激素无效ITP具有较好的疗效和安全性,值得在经济条件落后地区及基层医院推广。
Objective To investigate the clinical efficacy and safety of recombinant human interleukin-Ⅱ (rhIL-Ⅱ) combined with vincristine in the treatment of patients with steroid-induced idiopathic thrombocytopenic purpura (ITP). Methods From December 2008 to December 2011 in our hospital hematology inpatient treatment of 112 patients with ITP inactive hormone as the research object, the use of random number table method the patients were divided into control group and observation group. Patients in the control group were treated with vincristine, while patients in the observation group were treated with rhIL-II. The clinical efficacy and adverse drug reactions in the control group and observation group were compared. Results The total effective rate (85.71%) in observation group was significantly higher than that in control group (69.64%), the difference was statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion The combination of rhIL-Ⅱ and vincristine in the treatment of steroid-refractory ITP has good curative effect and safety. It is worth to be popularized in economically disadvantaged areas and primary hospitals.